Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ126712690,96
KB9899910,25
PKN144,18144,361,71
Msft5,45
Nokia12,92512,9353,32
IBM12,71
Mercedes-Benz Group AG51,7751,8-0,79
PFE0,15
01.06.2026 9:12:00
Indexy online
AD Index online
select
AD Index online
 

  • 29.05.2026
Zoetis Inc, Ordinary, New York Consolidated (ZTS, NY Consolidated)
Závěr k 29.5.2026 Změna (%) Změna (USD) Objem obchodů (USD)
77,69 -0,74 -0,58 438 256 345
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiZoetis Inc
TickerZTS
Kmenové akcie:Ordinary Shares Class A
Kmenové akcie:Ordinary Shares Class B
RICZTS
ISIN-
Poslední známé roční výsledky31.12.2025
Poslední známé čtvrtletní výsledky31.03.2026
Počet zaměstnanců k 31.12.2025 14 500
Akcie v oběhu k 01.05.2026 419 228 118
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice10 Sylvan Way
MěstoPARSIPPANY
PSČ07054
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 026 587 581
Fax13026555049

Business Summary: Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Financial Summary: BRIEF: For the three months ended 31 March 2026, Zoetis Inc revenues increased 2% to $2.26B. Net income decreased 5% to $601M. Revenues reflect International segment increase of 14% to $1.15B, Other emerging markets segment increase of 17% to $291M, Other Developed segment increase of 27% to $169M. Net income was offset by Selling, General and Administrative Exp increase of 4% to $588M (expense).
Odvětvová klasifikace
TRBC2012Veterinary Drugs
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSVeterinary Services
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPet Care (except Veterinary) Services
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICVeterinary Services, Specialties
SICDiagnostic Substances
SICCommercial Physical Research
SICAnimal Specialty Services



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorKristin Peck5401.01.2020
Chief Financial Officer, Executive Vice PresidentWetteny Joseph5301.06.202101.06.2021
Chief Human Resources Officer, Executive Vice President and Global OperationsJulie Fuller52
Executive Vice President, Chief Digital and Technology OfficerKeith Sarbaugh4711.11.202411.11.2024
Executive Vice President, General Counsel, Corporate SecretaryRoxanne Lagano61
Executive Vice President, President - Global Manufacturing and SupplyNicholas Ashton53
Executive Vice President - Corporate Affairs, Communications, Chief Sustainability OfficerJeannette Astorga51
Executive Vice President, Chief Commercial OfficerJamie Brannan5311.11.202401.11.2022
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevicesRimma Driscoll53
Executive Vice President, President - Research & DevelopmentKevin Esch4901.01.202601.01.2026